Severe allergic rhinitis (AR) is a chronic immunoglobulin E (IgE)-mediated respiratory response to seasonal and/or perennial environmental allergens. Treatment options include intranasal corticosteroids, antihistamines, mast cell stabilizers, decongestants, leukotriene antagonists, and anticholinergics. In addition, allergen immunotherapy (AIT) can target specific environmental allergies and change the patient’s immune system response to the allergen. Off-label biological therapies that target circulating free IgE, such as Roche / Novartis’s Xolair, offer an alternative therapeutic approach to treating the disease. Although most patients, especially those with mild to moderate disease, can control their AR using currently available therapies, individuals with more-severe disease could benefit from additional treatments. AITs in development and biological therapies with novel mechanisms of action will expand physicians’ arsenal of treatment options and fuel competition in the severe AR therapy market.

QUESTIONS ANSWERED

  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current inhaled therapies (e.g., Boehringer Ingelheim’s Atrovent) and allergen immunotherapies (e.g., Merck’s Ragwitek, Stallergenes Greer’s Oralair) perform on key treatment drivers and goals in severe AR?
  • What are the prevailing areas of unmet need and opportunity in severe AR?
  • What trade-offs across different clinical attributes and prices are acceptable to U.S. and European physicians for a hypothetical new drug targeting severe AR?

Geographies – United States, France, Germany, United Kingdom

Primary Research – 30 U.S. allergists, 30 U.S. otolaryngologists, and 30 European pulmonologists / otolaryngologists

Key Metrics Included

  • Target Product Profile (TPP) simulator based on conjoint analysis methodology
  • Stated versus derived importance of product attributes on prescribing behavior
  • Assessment of current drug performance against treatment drivers and goals
  • Physician perceptions of unmet needs in the indication and related indications
  • Analysis of remaining drug development opportunities

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Detailed, Expanded Analysis: Severe Allergic Rhinitis (US/EU)
    • Executive Summary
      • Unmet Need - Severe Allergic Rhinitis - Executive Summary - June 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Severe Allergic Rhinitis
      • Key Findings: Unmet Need in Severe Allergic Rhinitis and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Severe Allergic Rhinitis Market and Emerging Therapy Insights
        • Opportunity: Treatments Offering Less-Burdensome Administration
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Severe Allergic Rhinitis Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulation of a Market Scenario
        • Market Scenario
    • Appendix
      • Experts Interviewed
      • Bibliography

Author(s): Shubhendu Ghosh, PhD

Shubhendu Ghosh, is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, with a primary focus on asthma. Prior to joining DRG, Shubhendu was an Associate Editor at Nature Structural & Molecular Biology and a Copy Editor at Nature Medicine. He was also a Scientific and Developmental Editor at Nature Research Editing Service. Shubhendu received his in Biomedical Sciences from the University of Massachusetts Medical School after completing a B. Sc. in Microbiology from Delhi University and an M. Sc. In Biotechnology from Madurai Kamaraj University.


Related Reports

Allergic Rhinitis | Special Topics | Allergic Respiratory Disorders | Special Topics | US

Allergic respiratory disorders—such as allergic rhinitis, chronic rhinosinusitis, and nasal polyps—are characterized by activation of inflammatory pathways and the production of immun...

View Details